Qual é o preço para Frequency Therapeutics, Inc. (FREQ)

O preço para Frequency Therapeutics, Inc. (FREQ) é $0.2996

Qual é a capitalização de mercado para Frequency Therapeutics, Inc. (FREQ)

A capitalização de mercado para Frequency Therapeutics, Inc. (FREQ) é $10.58M

Frequency Therapeutics, Inc. (FREQ) Índice P/V

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing treatments that unlock the body's inherent capacity for regeneration to restore impaired functions. Their "Progenitor Cell Activation" approach leverages small molecules to stimulate progenitor cells within the body, encouraging the formation of new, functional tissues. The company's flagship product candidate, FX-322, is currently in Phase IIa clinical trials, aiming to address the fundamental cause of sensorineural hearing loss. Beyond this, Frequency is also advancing therapies for various degenerative diseases, including multiple sclerosis, and ailments impacting muscles, the gastrointestinal system, skin, and bones. For the development and commercialization of FX-322, the company holds a license and collaboration agreement with Astellas Pharma Inc. Additionally, it maintains collaboration and licensing agreements with esteemed organizations such as Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Founded in 2014, Frequency Therapeutics, Inc. is headquartered in Lexington, Massachusetts.

Ano	Rácio P/S	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

Rácio P/S

Alterar

Não há dados suficientes para as datas fornecidas.

Empresa	Rácio P/S	Diferença do rácio P/S	País
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	-	US
Argenx SE ARGX.US	10.13	-	NL
CSL Limited CSL.AX	2.95	-	AU
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	4.74	-	BE

Empresa

Rácio P/S

Diferença do rácio P/S

País